The addition of PSK to maintenance chemotherapy was also found to improve the survival rate of patients with acute myelogenous leukaemia (AML)63 but this was short of statistical significance (p =0.105). However, patients who remained in remission for 270 days benefited for a further 418 days on PSK.

In another study, PSK was effective in preventing relapse in childhood acute lymphoblastic leukaemia following treatment with chemotherapy but the benefit was also not statistically significant64. While showing no significant clinical benefit, no adverse side-effects were noted with PSK use in this paediatric population.